Demographic characteristics, clinical and laboratory features, and the distribution of pathogenic variants in the CFTR gene in the Cypriot cystic fibrosis (CF) population demonstrate the utility of a national CF patient registry

被引:7
作者
Yiallouros, Panayiotis K. [1 ,2 ]
Matthaiou, Andreas M. [1 ]
Anagnostopoulou, Pinelopi [1 ,2 ]
Kouis, Panayiotis [1 ]
Libik, Malgorzata [8 ,9 ]
Adamidi, Tonia [3 ]
Eleftheriou, Adonis [4 ]
Demetriou, Artemios
Ioannou, Phivos [2 ]
Tanteles, George A. [6 ,7 ]
Costi, Constantina [5 ]
Fanis, Pavlos [5 ,6 ]
Macek, Milan [8 ,9 ]
Neocleous, Vassos [5 ,6 ]
Phylactou, Leonidas A. [5 ,6 ]
机构
[1] Univ Cyprus, Shacolas Educ Ctr Clin Med, Med Sch, Resp Physiol Lab, 215-6 Palaios Dromos Lefkosias Lemesou, CY-2029 Nicosia, Cyprus
[2] Hosp Archbishop Makarios III, Paediat Pulmonol Unit, Nicosia, Cyprus
[3] Nicosia Gen Hosp, Pulmonol Clin, Nicosia, Cyprus
[4] Paphos Gen Hosp, Pulmonol Clin, Paphos, Cyprus
[5] Cyprus Inst Neurol & Genet, Dept Mol Genet Funct & Therapy, Nicosia, Cyprus
[6] Cyprus Inst Neurol & Genet, Cyprus Sch Mol Med, Nicosia, Cyprus
[7] Cyprus Inst Neurol & Genet, Dept Clin Genet, Nicosia, Cyprus
[8] Charles Univ Prague, Fac Med 2, Dept Biol & Med Genet, Prague, Czech Republic
[9] Charles Univ Prague, Motol Univ Hosp, Prague, Czech Republic
关键词
CFTR gene; CFTR modulators; Cystic fibrosis; Next-generation sequencing; Patient registry; MUTATIONAL SPECTRUM; REARRANGEMENTS; IVACAFTOR; DIAGNOSIS; IDENTIFICATION; EPIDEMIOLOGY; GUIDELINES; TEZACAFTOR; COMMON; 1ST;
D O I
10.1186/s13023-021-02049-z
中图分类号
Q3 [遗传学];
学科分类号
071007 ; 090102 ;
摘要
Background Specialized clinical care for cystic fibrosis (CF) in Cyprus, a small island country, has been implemented since the 1990s. However, only recently, a national CF patient registry has been established for the systematic recording of patients' data. In this study, we aim to present data on the epidemiological, genotypic and phenotypic features of CF patients in the country from the most recent data collection in 2019, with particular emphasis on notable rare or unique cases. Results Overall, data from 52 patients are presented, 5 of whom have deceased and 13 have been lost to follow-up in previous years. The mean age at diagnosis was 7.2 +/- 12.3 years, and the mean age of 34 alive patients by the end of 2019 was 22.6 +/- 13.2 years. Patients most commonly presented at diagnosis with acute or persistent respiratory symptoms (46.2%), failure to thrive or malnutrition (40.4%), and dehydration or electrolyte imbalance (32.7%). Sweat chloride levels were diagnostic (above 60 mmol/L) in 81.8% of examined patients. The most common identified mutation was p.Phe508del (F508del) (45.2%), followed by p.Leu346Pro (L346P) (6.7%), a mutation detected solely in individuals of Cypriot descent. The mean BMI and FEV1 z-scores were 0.2 +/- 1.3 and - 2.1 +/- 1.7 across all age groups, respectively, whereas chronic Pseudomonas aeruginosa colonization was noted in 26.9% of patients. The majority of patients (74.5%) were eligible to receive at least one of the available CFTR modulator therapies. In 25% of patients we recovered rare or unique genotypic profiles, including the endemic p.Leu346Pro (L346P), the rare CFTR-dup2, the co-segregated c.4200_4201delTG/c.489 + 3A > G, and the polymorphism p.Ser877Ala. Conclusions CF patient registries are particularly important in small or isolated populations, such as in Cyprus, with rare or unique disease cases. Their operation is necessary for the optimization of clinical care provided to CF patients, enabling their majority to benefit from evolving advances in precision medicine.
引用
收藏
页数:12
相关论文
共 45 条
[41]   Qualitative and quantitative analysis of mRNA associated with four putative splicing mutations (621+3A→G, 2751+2T→A, 296+1G→C, 1717-9T→C-D565G) and one nonsense mutation (ES22X) in the CFTR gene [J].
Tzetis, M ;
Efthymiadou, A ;
Doudounakis, S ;
Kanavakis, E .
HUMAN GENETICS, 2001, 109 (06) :592-601
[42]   Lumacaftor-Ivacaftor in Patients with Cystic Fibrosis Homozygous for Phe508del CFTR [J].
Wainwright, C. E. ;
Elborn, J. S. ;
Ramsey, B. W. ;
Marigowda, G. ;
Huang, X. ;
Cipolli, M. ;
Colombo, C. ;
Davies, J. C. ;
De Boeck, K. ;
Flume, P. A. ;
Konstan, M. W. ;
McColley, S. A. ;
Mccoy, K. ;
McKone, E. F. ;
Munck, A. ;
Ratjen, F. ;
Rowe, S. M. ;
Waltz, D. ;
Boyle, M. P. .
NEW ENGLAND JOURNAL OF MEDICINE, 2015, 373 (03) :220-231
[43]   Mutation in the gene responsible for cystic fibrosis and predisposition to chronic rhinosinusitis in the general population [J].
Wang, XJ ;
Moylan, B ;
Leopold, DA ;
Kim, J ;
Rubenstein, RC ;
Togias, A ;
Proud, D ;
Zeitlin, PL ;
Cutting, GR .
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 2000, 284 (14) :1814-1819
[44]   Clinical features and treatment approaches in cystic fibrosis with pseudo-Bartter syndrome [J].
Yalçin, E ;
Kiper, N ;
Dogru, D ;
Özçelik, U ;
Aslan, AT .
ANNALS OF TROPICAL PAEDIATRICS, 2005, 25 (02) :119-124
[45]   Cystic fibrosis mutational spectrum and genotypic/phenotypic features in Greek-Cypriots, with emphasis on dehydration as presenting symptom [J].
Yiallouros, P. K. ;
Neocleous, V. ;
Zeniou, M. ;
Adamidou, T. ;
Costi, C. ;
Christophi, C. ;
Tzetis, M. ;
Kanavakis, E. ;
Deltas, C. .
CLINICAL GENETICS, 2007, 71 (03) :290-292